

Annual Scientific Meeting 2025 PROGRAM

Monday 4 August 2025	2
Tuesday 5 August 2025	3
Wednesday 6 August 2025	4
Thursday 7 August 2025	6
Friday 8 August 2025	8
Friday 8 August 2025	9



Please note: All ASM delegates are welcome to attend CLL Spotlight, Lunch'n'Learn and Lymphoma Symposium and/or the SIG Workshops

	Monday 4 August 2025 FACT ACCREDITATION TRAINING
8:30am - 4:30pm	FACT Accreditation Training - Bay Room, Level 3 – (by invitation/EOI) (followed by FACT Dinner)



Please note: All ASM delegates are welcome to attend CLL Spotlight, Lunch'n'Learn and Lymphoma Symposium and/or the SIG Workshops

FACT	Tuesday 5 August 2025 ACCREDITATION TRAINING / SIG WORKSHOPS / SATELLITE SYMPOSIUM	
8:30am - 4:00pm	FACT Accreditation Training - Wharf Room, Level 3 (by invitation/EOI)	
9:30am - 5:30pm 10:00am - 3:00pm 8:45am - 4:00pm	 ANZTCT & CIBMTR Data Manager Workshop (Bay Room, Twin Towns Conference Centre) ANZTCT Nursing Workshop (Kirra Room, Rydges Gold Coast Airport) ANZTCT Pharmacy Education Day (Bilinga Room, Rydges Gold Coast Airport) 	
11:00am - 11:30am	Registration - Visions Foyer (Ground Floor, Twin Towns Resort)	
11:30am - 12:30pm	 CLL Spotlight - Sponsored by Eli Lilly Chair: Mary Ann Anderson Case presentations of double refractory CLL - Sean McKeague Emerging therapeutic options in exposed double CLL - Dr Kate Manos Cellular therapies outcomes - Prof Nada Hamad 	
12:30pm - 1:00pm	Lunch'n'Learn with Dr Olalekan Oluwole: Building a Successful CAR-T Program - Sponsored by Gilead	
1:30pm - 5:30pm	 ANZTCT LYMPHOMA SATELLITE SYMPOSIUM - Sponsored by AbbVie Opened by A/Prof Mary Ann Anderson 	
1:30pm – 2:40pm	 Focus on DLBCL - Chair: Dr Allison Barraclough and Dr Morag Whyte Emerging approaches in DLBCL lymphoma - Dr Anna Sureda The future of Cellular therapies (CART, autograft) - Dr Fiona Swain Panel discussion - Prof Cameron Turtle, Dr John Kuruvilla, Dr Anna Sureda, Dr Fiona Swain, Prof Judith Trotman 	
2:40pm – 2:55pm	Coffee break	
2:55pm – 4:05pm	 Focus on Follicular Lymphoma - Chair: Dr Josh Tobin Emerging approaches in FL - Dr John Kuruvilla The future of TCT in FL - A/Prof Amit Khot Panel Discussion - Prof Cameron Turtle, Dr John Kuruvilla, Dr Anna Sureda, A/Prof Amit Khot, Prof Judith Trotman 	
4:05pm - 4:20pm	Coffee Break	
4:20pm - 5:30pm	 Focus on Mantle Cell Lymphoma - Chair: Prof Jake Shortt Emerging approaches in MCL - Dr Adrian Minson Cellular therapies (CART, allo) - A/Prof Andrea Henden Panel discussion - Dr John Kuruvilla, Dr Anna Sureda, Dr Kate Manos, A/Prof Andrea Henden, Dr Adrian Minson 	
6:30pm	Lymphoma dinner (by invitation - faculty and speakers) Kindly note this program is subject to change	



	Wednesday 6 August 2025 ANZTCT ASM 2025 - DAY 1
From 7:30am	Registration – Stars, Showroom Foyer (Level 5, Twin Towns Conference Centre)
8:00am	Opening of ANZTCT ASM 2025 Chairs: Prof Nada Hamad and A/Prof Mary Ann Anderson • Welcome to Country: Clinton Brewer, proud Kombumerri man and YRACA Director • Maori Address: Nadene Edmonds • President's Address
The rapidl	y changing world of TCT - Chairs: Karen Maddock and Dr Allison Barraclough
8:30am	 Keynote Presentation - The future of TCT in Lymphoma Dr John Kuruvilla - Princess Margaret Cancer Centre
9:15am	Session: Complications of CAR-T Neuro • A/Prof Mastura Monif - The Alfred Hospital CRS: Haem • Prof Cameron Turtle - The University of Sydney Infection • Dr Gemma Reynolds - Peter MacCallum Cancer Centre
10:30am	Morning Tea - Sponsored by Sobi
11:00am	 Oral Abstracts: Presidential Chairs: Dr Duncan Purtill and Prof Nada Hamad Alia Cibich - Improved survival after allogeneic HSCT over the last 35 years is driven by reduced non-relapse mortality: A Statewide Australian cohort analysis Daniel Kilmartin - Let's make Quality great again Nancy Kim - Health resource utilisation and costs of allogeneic hematopoietic stem cell transplantation: an Australian data linkage study Clair Scott - Validation of a Mononuclear Cell (MNC) Collection calculation to optimise CAR-T Leukapheresis. Fiona Stanley Hospital (FSH) experience



		Wednesday 6 August 2025	
		Wednesday 6 August 2025 ANZTCT ASM 2025 - DAY 1	
12:00pm	Delegate Lunch – Level 5	Panel Discussion: How should stakeholders collaborate to deliver on the promise of TCT? (12:00pm - 12:40pm, Bay Room - Level 3) Moderated by: Prof Nada Hamad Panellists include: Dr Edward Abadir (RPAH), A/Prof Mary Ann Anderson (Peter Mac), Prof Jonathan Craig (MSAC) and Suchit Handa (ACSQHC)	
		Lunch 'n' Learn (12:50pm - 1:20pm, Showroom, Level 5) with Prof Selim Corbacioglu: The pros and cons of implementing the pediatric EBMT criteria in the adult setting Sponsored by Jazz Pharmaceuticals Chair: A/Prof Shaun Fleming	
Chair: Pro	f Paula Marlton		
1:30pm	 Patient-led story - Robert Cormack Panel session: The future of lymphoma TCT logistics Moderated by: Prof David Yeung Panellists: Dr Anna Sureda, Prof Rob Weinkove, Dr Olalekan Oluwole, Prof Jonathan Craig, Dr Tina Albertson 		
2:30pm	 Oral Abstracts: Transplant theme Chairs: Prof Paula Marlton and Dr Fiona Swain Sarah Anderson - Enteral prebiotic fibre supplementation and the impact on the microbiome post allogeneic transplantation Lily Rush - Post-transplant cyclophosphamide dosed by total body weight leads to delay of platelet engraftment in the obese Heather Weerdenburg - Posaconazole in Paediatrics: Are We Hitting the Mark or Missing the Target? Xiaowen Wu - The effectiveness of pre-transplant interventions in ABO mismatched allogeneic stem cell transplant - a single centre review 		
3:30pm	Afternoon Tea - Sponsored by Arovella		
4:00pm	Debates: The role of transplant in lymphoma or is CAR-T the new standard Role of Allo in high grade lymphoma • Prof Rob Weinkove (Affirmative) Vs Dr Allison Barraclough (Negative) Role of Allo in low grade lymphoma • Prof David Ritchie (Affirmative) Vs Prof Judith Trotman (Negative)		
5:00pm - 6:00pm	Posters and Welc	ome Drinks - Stars, Showroom Foyer - Level 5	



		Thursday 7 August 2025 ANZTCT ASM 2025 - DAY 2	
Future of A	Allo-BMT - Chairs: Yvonn	ne Panek-Hudson and Dr Shanti Ramachandran	
8:30am	Keynote Plenary: GVHD diagnosis, staging, prophylaxis, and treatment The future of GVHD and the role of Biomarkers • Dr Kirk Schultz - BC Children's Hospital The future of long term follow up • John Murray - The Christie NHS Foundation Trust		
9:30am	Session: Registry science and its value Keynote Presentation: How CIBMTR and registry science lifts up our game (40-mins) • Dr Wael Saber - CIBMTR MCW Registry update: Exciting changes in the ANZTCT registry (10-mins) • Leonie Wilcox - ANZTCT Registry		
	 National initiatives that support registry science and clinical quality (10-mins) Suchit Handa - Australian Commission on Safety and Quality in Health Care 		
10:30am	Morning Tea - Sponsored by Sobi		
11:00am	Session: Supporting best outcomes Chairs: Daniel Kilmartin and A/Prof Carmel O'Brien Energy expenditure during allogeneic transplantation • Rachel Willims The impact of exercise on immunity and the microbiome during transplantation • Morgan Farley Rehabilitation and Nutritional Support following BMT • Dr Chris Swain		
12:00pm	Delegate Lunch – Level 5	ANZTCT AGM (12:00pm - 12:30pm, Horizons Room - Level 3) Lunch 'n' Learn (12:45pm - 1:15pm, Showroom - Level 5) with Dr Kate Markey - Fred Hutch: The role of the microbiome in immune recovery after transplant Sponsored by MNK Chair: Dr Ashleigh Scott	



		Thursday 7 August 2025 ANZTCT ASM 2025 - DAY 2
Future of 1	Transplant - Chairs: Pro	f Peter Shaw and Dr John Kwan
1:30pm		: What is the next innovation in allo-BMT: Future Paradigm Shifts Hospital Universitario de Salamanca
2:15pm	Moderated by: YvonPanellists: Prof DaviArrow Foundation up	are making BMT safer, how do we make it kinder? ne Panek-Hudson id Ritchie, Nicole Loft, Dr Wael Saber, Dr Kate Markey
3:30pm	Afternoon Tea - Sponsored by Arovella	Nursing Committee AGM (Bay Room, Level 3)
4:00pm	 Oral Abstracts: Multidisciplinary TCT Chairs: A/Prof Shaun Fleming and Celeste Hill Genevieve Douglas - The Australian Index of Relative Socioeconomic Disadvantage Predicts Long-term Health-Related Quality of Life Outcomes in Allogeneic Haematopoietic Stem Cell Transplant Survivors Dr Salvatore Fiorenza - A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial Teresa Garcia - Long-term follow up care after allogeneic bone marrow transplant: 10-year retrospective analysis of a single centre Australian nurse-led (NP and CNC) long-term follow-up clinic Min-Hi Han - Outcomes and treatment determinants in intermediate-adverse risk acute leukaemia: Analysis of barriers to allogeneic stem cell transplant 	
5:00pm 6:30pm - 9:30pm	Delegate break ASM Dinner at Xenia (Coolangatta – Paint The Town RED with Arrow



Friday 8 August 2025 ANZTCT ASM 2025 - DAY 3			
Beyond the Cel	lls: Equity and Sustainal	bility of TCT - Chairs: Dr Richard Doocey and Prof Nada Hamad	
8:30am	Myeloma Keynote: Myeloma CART in the real world Access challenges and how to practice with an equity lens • Dr Gurbakhash Kaur - Mt Sinai		
9:30am	Session: High Quality Care is Equitable Care • Dr Timothy Prestidge - Starship Blood and Cancer Centre • Celeste Hill - Fiona Stanley Hospital • John Murray - The Christie NHS Foundation Trust		
10:30am	Morning Tea - Sponsored by Sobi		
11:00am	Session: Equity, diversity and inclusion in action Opened by Prof Nada Hamad Ethnicity, HLA and how this plays into donor sourcing and access • Dr Heather Dunckley - New Zealand Transplantation and Immunogenetics Laboratory A case of equity led research, funding and implementation • Prof Rajiv Khanna - Queensland Institute of Medical Research Service equity for long term transplant survivors – a patient centred approach • Gemma McErlean - University of Wollongong		
12:30pm	 Panel Discussion: Advocacy Initiatives Moderated by: Prof Nada Hamad Panellists: Dr Richard Doocey, Rosie Howard, Dr Duncan Purtill, Dr Scott Ragg 		
1:10pm	ANZTCT ASM 2025 Close		
1:15pm	Delegate Lunch – Level 3	HoD Meeting (1:15pm - 1:45pm, Showroom - Level 5)	
		Lunch n Learn (1:45pm - 2:15pm, River Room - Level 3) with Dr Gurbakhash Kaur Triage and timing of patients for CAR-T cell therapies for myeloma: A message from the future Sponsored by Johnson & Johnson Chair: Prof Andrew Spencer	



Friday 8 August 2025 ANZTCT SPOTLIGHT SESSION		
ANZTCT SPOTLIGHT SESSION: The rapidly evolving TCT landscape in Multiple Myeloma (River Room - Level 3) Opened by Dr Salvatore Fiorenza		
Looking Backw	vards in Myeloma - Chair: Dr Leanne Berkahn	
2:15pm – 3:25pm	 Myeloma treatment in octogenarians and beyond Prof Andrew Spencer (Discussion to follow) Have we completely optimised autologous stem cell transplantation in Myeloma? Dr Karthik Nath (Discussion to follow) 	
3:25pm	Coffee break - Sponsored by Arovella	
Looking Forwa	rds in Myeloma - Chair: Prof Joy Ho	
3:40pm – 5:30pm	 T cell engaging antibody therapies in Myeloma: The science and the clinical outcomes Dr Sueh-Li Lim (Discussion to follow) Secondary primary malignancies in Myeloma patients undergoing ASCT and CAR-T therapy: How worried should we be? Dr Cindy Lee (Discussion to follow) Debate: Not Everyone Deserves CAR-T Cell Therapy for Myeloma Dr Krystal Bergin (Affirmative) Vs Dr Gurbakhash Kaur (Negative) Debate: Allograft is dead in Myeloma Dr Matthew Rees (Affirmative) Vs Dr Adam Bryant (Negative) 	
6:00pm	Myeloma dinner (by invitation - faculty and speakers) - supported by Johnson & Johnson	



Clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.



Developing off-the-shelf CAR-T cell therapies to provide **broad** access and rapid treatment for patients with hematologic malignancies.

Next-generation **chRDNA** (**CRISPR hybrid RNA-DNA**) **genome-editing technology** that is intended to achieve superior specificity and precision.






Caribou's cell therapies are armored through multiple genome-editing strategies, including checkpoint disruption and immune cloaking to increase **antitumor activity**.

Caribou has two ongoing Phase 1 clinical trials for hematologic diseases

CB-010 ANTLER clinical trial PD-1 KO CB-010 Anti-CD19 CAR TCR KO

CB-010 is an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO) being evaluated in the ANTLER Phase 1 clinical trial for relapsed or refractory B cell non-Hodgkin lymphoma.



CB-011 is an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking being evaluated in the CaMMouflage Phase 1 clinical trial for relapsed or refractory multiple myeloma.



Scan or visit www.cariboubio.com to learn more about Caribou's chRDNA genome-editing technology and clinical programs